Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Forman

Showing results (1021-1030 of 1,052) with videos related to

Pageof 106
Sort By:
Haematologica|October 4, 2017
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of <i>TP53</i> mutational statusIbrahim Aldoss, Anh Pham, Sierra Min Li, et al.
Blood Advances|October 12, 2021
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphomaAlex F Herrera, Joycelynne Palmer, Vikram Adhikarla, et al.
Blood Advances|July 11, 2022
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALLIbrahim Aldoss, Dongyun Yang, Vanina Tomasian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2000
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trialN J Chao, D S Snyder, M Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Blood Advances|January 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALLIbrahim Aldoss, Shanpeng Li, Jianying Zhang, et al.
Blood Advances|June 5, 2024
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphomaJasmine Zain, Ni-Chun Tsai, Joycelynne Palmer, et al.
Nature Communications|February 20, 2026
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapyLior Goldberg, Eric R Haas, Jiaqi Wu, et al.
Nature Communications|February 1, 2025
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escapeFang Chen, Dandan Zhao, Yongfang Xu, et al.
Leukemia|April 17, 2020
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targetingDomenico Viola, Ada Dona, Enrico Caserta, et al.
Pageof 106

Showing results (1021-1030 of 1,052) with videos related to

Sort By:
Pageof 106
Haematologica|October 4, 2017
Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of <i>TP53</i> mutational statusIbrahim Aldoss, Anh Pham, Sierra Min Li, et al.
Blood Advances|October 12, 2021
Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphomaAlex F Herrera, Joycelynne Palmer, Vikram Adhikarla, et al.
Blood Advances|July 11, 2022
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALLIbrahim Aldoss, Dongyun Yang, Vanina Tomasian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 28, 2000
Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trialN J Chao, D S Snyder, M Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 8, 2019
Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 TrialRichard F Ambinder, Juan Wu, Brent Logan, et al.
Blood Advances|January 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALLIbrahim Aldoss, Shanpeng Li, Jianying Zhang, et al.
Blood Advances|June 5, 2024
Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphomaJasmine Zain, Ni-Chun Tsai, Joycelynne Palmer, et al.
Nature Communications|February 20, 2026
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapyLior Goldberg, Eric R Haas, Jiaqi Wu, et al.
Nature Communications|February 1, 2025
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escapeFang Chen, Dandan Zhao, Yongfang Xu, et al.
Leukemia|April 17, 2020
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targetingDomenico Viola, Ada Dona, Enrico Caserta, et al.
Pageof 106